Real-time Euronext Bruxelles 12:35:26 2024-03-28 pm EDT 5-day change 1st Jan Change
0.0002 EUR +100.00% Intraday chart for Oxurion NV 0.00% -77.78%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Oxurion Raises Additional Funds from Convertible Bonds Issue MT
Oxurion Seeks Healthcare Mergers Under New Corporate Strategy MT
Belgium's Oxurion Secures Funding, Evades Bankruptcy; CEO/CFO to Step Down MT
Oxurion Announces CEO Changes CI
Oxurion Announces Management Changes CI
Oxurion Announces CFO Changes CI
Oxurion NV Discloses Topline Data from Kalahari Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema CI
Oxurion Receives EUR1 Million from Atlas Special Opportunities MT
Belgium's Oxurion Secures EUR1.5 Million Funding for Clinical Trial MT
Oxurion NV Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Oxurion Signs Deals to Advance Diabetic Macular Edema Therapy MT
Oxurion Issues EUR1 Million Bonds to Atlas MT
Oxurion NV Reaches Enrollment Target in Kalahari Phase 2, Part B Trial of Novel Pkal Inhibitor Thr-149 in Diabetic Macular Edema CI
Oxurion NV Auditor Raises 'Going Concern' Doubt CI
Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Oxurion NV Announces Board Changes CI
Oxurion NV Provides Update on Recruitment for Kalahari Phase 2, Part B Trial of Novel Pkal Inhibitor THR 149 in Diabetic Macular Edema CI
Oxurion NV announced that it expects to receive €20.8 million in funding CI
Oxurion NV announced that it has received ?11 million in funding from Negma Group Ltd. CI
Oxurion NV Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macular Edema Following Interim Analysis CI
Oxurion NV Announces Interim Analysis for KALAHARI Trial CI
Oxurion NV Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Oxurion NV Announces Preclinical Presentation on THR-149 at KININ2022 CI
Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema CI
Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology Annual Meeting CI
Chart Oxurion NV
More charts
Oxurion NV is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide. Oxurion NV is aiming to build the leading global franchise in the treatment of DME, based on the successful clinical development of its two novel therapeutics: THR-149, a plasma kallikrein inhibitor being developed as a potential new standard of care for DME patients who respond sub-optimally to anti-VEGF therapy, and THR-687, a pan-RGD integrin inhibitor, initially being developed as a potential new standard of care for all DME patients.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Annual profits - Rate of surprise